← ANALYST RATINGS · TIPRANKS
Maze Therapeutics, Inc. (MAZE): analyst forecast and price target
Analyst consensus
Strong Buy6 Buy0 Hold0 Sell
Ratings of 6 analysts in the last 3 months · top analysts only12-month forecast
Based on 6 price targets given in the last 3 months, the average target is $62.50, the highest $110, the lowest $46.00. The average is +127.0% from the last price of $27.53.
Analyst ratings 15
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Sadia Rahman★★★★★★★★★★#5292 · hits 70% · avg +11.8% | Wells Fargo | $55.00 | Buy | +99.8% | Reiterated | 15.10.26on TipRanks 07:30 | +4.5%next day +1.3% | ↗ |
| Ananda Ghosh★★★★★★★★★★#1171 · hits 53% · avg +20.8% | H.C. Wainwright | $110 | Buy | +299.6% | Reiterated | 05.10.26on TipRanks 06:55 | −0.7%next day −0.5% · 5 days +4.4% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $23.00 → $29.00+26.1% | Hold | +5.3% | Reiterated | 23.09.26on TipRanks 14:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $21.50 → $28.00+30.2% | Hold | +1.7% | Reiterated | 23.09.26on TipRanks 14:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $22.00 → $28.00+27.3% | Hold | +1.7% | Reiterated | 23.09.26on TipRanks 14:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $21.00 → $28.00+33.3% | Hold | +1.7% | Upgrade | 23.09.26on TipRanks 14:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $22.00 → $29.00+31.8% | Hold | +5.3% | Reiterated | 23.09.26on TipRanks 14:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $22.50 → $29.00+28.9% | Hold | +5.3% | Reiterated | 23.09.26on TipRanks 14:05 | — | |
| Laura Chico★★★★★★★★★★#527 · hits 54% · avg +14.2% | Wedbush | $48.00 | Buy | +74.4% | Reiterated | 23.09.26on TipRanks 09:08 | −0.3%next day −6.6% · 5 days −2.6% | ↗ |
| Eric Joseph★★★★★★★★★★#1258 · hits 52% · avg +11.4% | Citi | $50.00 | Buy | +81.6% | Initiated | 23.09.26on TipRanks 05:25 | −0.3%next day −6.6% · 5 days −2.6% | ↗ |
| Julian Harrison★★★★★★★★★★#42 · hits 57% · avg +53.4% | BTIG | $46.00 | Buy | +67.1% | Reiterated | 22.09.26on TipRanks Sep 23 05:55 | +26.8%next day −0.3% · 5 days −3.6% | ↗ |
| Rami Katkhuda★★★★★★★★★★#297 · hits 55% · avg +31.7% | LifeSci Capital | $57.00 | Buy | +107.0% | Reiterated | 22.09.26on TipRanks 15:55 | +26.8%next day −0.3% · 5 days −3.6% | ↗ |
| Danielle Brill★★★★★★★★★★#566 · hits 56% · avg +16.1% | Truist Financial | $64.00 | Buy | +132.5% | Reiterated | 22.09.26on TipRanks 10:35 | +26.8%next day −0.3% · 5 days −3.6% | ↗ |
| Ananda Ghosh★★★★★★★★★★#1171 · hits 53% · avg +20.8% | H.C. Wainwright | $110 | Buy | +299.6% | Reiterated | 22.09.26on TipRanks 10:35 | +26.8%next day −0.3% · 5 days −3.6% | ↗ |
| Sadia Rahman★★★★★★★★★★#5292 · hits 70% · avg +11.8% | Wells Fargo | $50.00 → $55.00+10.0% | Buy | +99.8% | Reiterated | 09.09.26on TipRanks Sep 10 06:10 | −6.3%next day +1.6% · 5 days −1.6% | ↗ |
| Salim Syed★★★★★★★★★★#7609 · hits 44% · avg +0.2% | Mizuho Securities | $97.00 | Buy | +252.3% | Reiterated | 23.06.26on TipRanks 10:10 | +4.7%next day +1.0% · 5 days +11.2% | ↗ |
| Anupam Rama★★★★★★★★★★#291 · hits 54% · avg +23.3% | J.P. Morgan | $58.00 → $53.00−8.6% | Buy | +92.5% | Reiterated | 22.05.26on TipRanks May 23 08:06 | −0.3%next day +1.5% · 5 days −3.0% | ↗ |
| Tyler Van Buren★★★★★★★★★★#42 · hits 64% · avg +38.8% | TD Cowen | — | Buy | — | Reiterated | 12.05.26on TipRanks 19:55 | +4.0%next day −2.8% · 5 days −7.0% | ↗ |
| Martin Auster★★★★★★★★★★#1128 · hits 51% · avg +16.1% | Raymond James | $56.00 | Buy | +103.4% | Reiterated | 25.03.26on TipRanks 11:45 | −35.8%next day +1.7% · 5 days −8.2% | ↗ |
| Joseph Schwartz★★★★★★★★★★#135 · hits 54% · avg +31.9% | Leerink Partners | $50.00 | Buy | +81.6% | Reiterated | 25.03.26on TipRanks 09:50 | −35.8%next day +1.7% · 5 days −8.2% | ↗ |
| Debjit Chattopadhyay★★★★★★★★★★#506 · hits 48% · avg +17.0% | Guggenheim | $46.00 → $58.00+26.1% | Buy | +110.7% | Assigned | 04.03.26on TipRanks 07:25 | +4.5%next day −2.0% · 5 days +9.8% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Maze Therapeutics, Inc.
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $61.43 at a price of $27.18 (+126.0%); now: $61.43 at $27.53 (+123.1%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 13 | 6 | 5 | 4 | 9 | 9 |
| Buy | 10 | 2 | 2 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.76 (from $-0.87 to $-0.56). Last quarter: $-0.76.
Best top-analyst consensus in the sector · Healthcare
About Maze Therapeutics, Inc.
- CEO: Jason Coloma
- Employees: 141
- 171 Oyster Point Blvd, South San Francisco, CA, 94080, US
- www.mazetx.com
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Data from the stock’s TipRanks forecast page, read 104 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗